Figure 2
Figure 2. Ex vivo analysis of TRBV usage by CPS- and FPT-specific T cells. PBMCs from healthy virus carriers were co-stained with pMHC pentamers (CPS or FPT) and a panel of TRBV monoclonal antibodies. Data based on fresh PBMCs is presented in panels A and B (for CPS-specific T cells) and panels C and D (for FPT-specific T cells). After in vitro culture these T cells were re-analyzed using pMHC-pentamers and a panel of TRBV monoclonal antibodies. Data for CPS-specific T-cell cultures is presented in panels E and F, while data for FPT-specific T cells is displayed in panels G and H. The results are expressed as percent pMHC-pentamer-specific cells. Data presented in panels A, C, E, and G are from donor 1; data in panel B and D are from donor 2; while data in panels F and H are from donor 6 (HLA A30, A32, B*3508, B42).

Ex vivo analysis of TRBV usage by CPS- and FPT-specific T cells. PBMCs from healthy virus carriers were co-stained with pMHC pentamers (CPS or FPT) and a panel of TRBV monoclonal antibodies. Data based on fresh PBMCs is presented in panels A and B (for CPS-specific T cells) and panels C and D (for FPT-specific T cells). After in vitro culture these T cells were re-analyzed using pMHC-pentamers and a panel of TRBV monoclonal antibodies. Data for CPS-specific T-cell cultures is presented in panels E and F, while data for FPT-specific T cells is displayed in panels G and H. The results are expressed as percent pMHC-pentamer-specific cells. Data presented in panels A, C, E, and G are from donor 1; data in panel B and D are from donor 2; while data in panels F and H are from donor 6 (HLA A30, A32, B*3508, B42).

Close Modal

or Create an Account

Close Modal
Close Modal